

(A Unit of KOS Healthcare)




Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

	LABORATORY REPORT						
Name	:Mrs MEENU DI	EVI	Sex/Age	: Fem	ale/29 Years	Case ID	:40821600513
Ref By	:DR. VIANY CHO	PRA	Dis.Loc.	:		Pt ID	:
Bill. Loc.	:KOS DIAGNOST	TIC LAB				Pt. Loc.	:
Registration Date & Time : 04-Aug-2024 09:32		Sample Typ	oe	: Heparin Whole Blood - Na	Ph#	:	
Sample Date & Time : 04-Aug-2024		: 04-Aug-2024 09:32	Sample Co	oll.By	:	Ref Id	:
Report Date & Time : 14-Aug-2024 13:46		Acc. Rema	arks	•	Ref Id 2	•	

Chromosome Analysis Report

Clinical History						
Karyotype (ISCN Nomenclature 2020)		46,XX				
<u>Interpretation</u>	Normal Karyotype					
Banding Method	: GTG	Culture Type	: 72hrs PHA stimulated			
Banding Resolution	: Approx 550	Metaphases Counted	: 20			
Metaphases Analyzed	: 20	Metaphase Karyotyped	: 05			
Proliferative Index	: Good	Quality of Metaphases	: Good			

For specimens received from non NCGM locations, it is presumed that it belongs to the patient as identified on the labels of the container/Test Requisition Formand it has been verified as per GCLP (Good Clinical Lab Practices) by the referrer at the time of collection of the specimen. NCGM's responsibility is limited to the analytical part of the assay performed.



Page 1 of 4





(A Unit of KOS Healthcare)




Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist


Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

	LABORATORY REPORT						
Name	:Mrs MEENU D	EVI	Sex/Age	: Fem	ale/29 Years	Case ID	:40821600513
Ref By	:DR. VIANY CHO	OPRA	Dis.Loc.	:		Pt ID	:
Bill. Loc.	:KOS DIAGNOS	TIC LAB				Pt. Loc.	:
Registration Date & Time : 04-Aug-2024 09:32		Sample Typ	oe	: Heparin Whole Blood - N	la Ph#	:	
Sample Da	ate & Time	: 04-Aug-2024 09:32	Sample Co	oll.By	:	Ref Id	:
Report Date & Time : 14-Aug-2024 13:46		Acc. Rema	arks	:	Ref Id 2	:	

Karyogram and Metaphase



For specimens received from non NCGM locations, it is presumed that it belongs to the patient as identified on the labels of the container/Test Requisition Formand it has been verified as per GCLP (Good Clinical Lab Practices) by the referrer at the time of collection of the specimen. NCGM's responsibility is limited to the analytical part of the assay performed.



Page 2 of 4





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

		LABORATO	RY REPORT			
Name	:Mrs MEENU D	EVI	Sex/Age	: Female/29 Years	Case ID	:40821600513
Ref By	:DR. VIANY CHO	OPRA	Dis.Loc.	:	Pt ID	:
Bill. Loc.	:KOS DIAGNOS	TIC LAB			Pt. Loc.	:
Registratio	n Date & Time	: 04-Aug-2024 09:32	Sample Type	: Heparin Whole Blood	- Na Ph#	:
Sample Da	te & Time	: 04-Aug-2024 09:32	Sample Coll	l.By :	Ref Id	:
Report Da	te & Time	: 14-Aug-2024 13:46	Acc. Remar	ks :	Ref Id 2	:

Limitation

The error rate of the test is 0.5%. The normal report does not rule out very Low grade mosaicism, minor chromosomal anomalies, and deletion, Duplication or Inversion at very subtle level. The report should be interpreted in accordance with the counselling provided before the test and with the report. A standard G-banded Karyotype usually has a resolution of around 5 Mb.

Disclaimer

Polymorphic variants have not been reported as these variants are not associated with specific disease or phenotype. Cytogenetically visible polymorphic variants include variants involving heterochromatin (variant size), satellite size, pericentric inversions (heterochromatic or euchromatic regions) [e.g., 1qh+/qh-, 9qh+/qh-, 16qh+/qh-, acrocentric p+ or p-, Yqh+/qh-, inv(9)(p11q13), inv(2)(p11.2q13)] and also euchromatic variants (e.g., located on 4p16, 8p23.1, 9p12, 9q13-q21.12, 15q11.2, 16p11.2).

Reference: Silva, M., de Leeuw, N., Mann, K., Schuring-Blom, H., Morgan, S., Giardino, D., Rack, K. and Hastings, R., 2019. European guidelines for constitutional cytogenomic analysis. European Journal of Human Genetics, 27(1), pp.1-16.

For specimens received from non NCGM locations, it is presumed that it belongs to the patient as identified on the labels of the container/Test Requisition Formand it has been verified as per GCLP (Good Clinical Lab Practices) by the referrer at the time of collection of the specimen. NCGM's responsibility is limited to the analytical part of the assay performed.

Dr. Samarth S. Bhatt Ph.D,EU Dip in Mol.Cytogenetics

Page 3 of 4





(A Unit of KOS Healthcare)




Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

	LABORATORY REPORT					
Name	:Mrs MEENU D	EVI	Sex/Age : Fe	male/29 Years	Case ID	:40821600513
Ref By	:DR. VIANY CHO	OPRA	Dis.Loc. :		Pt ID	:
Bill. Loc.	:KOS DIAGNOS	TIC LAB			Pt. Loc.	:
Registratio	n Date & Time	: 04-Aug-2024 09:32	Sample Type	: Heparin Whole Blood	- Na Ph#	:
Sample Da	te & Time	: 04-Aug-2024 09:32	Sample Coll.By	:	Ref Id	:
Report Da	te & Time	: 14-Aug-2024 13:46	Acc. Remarks		Ref Id 2	:

----- End Of Report -----

For specimens received from non NCGM locations, it is presumed that it belongs to the patient as identified on the labels of the container/Test Requisition Formand it has been verified as per GCLP (Good Clinical Lab Practices) by the referrer at the time of collection of the specimen. NCGM's responsibility is limited to the analytical part of the assay performed.



Page 4 of 4

